このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

GeoVax Labs 過去の業績

過去基準チェック /06

GeoVax Labsの収益は年間平均-48.2%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 49.6%割合で減少しています。

主要情報

-48.2%

収益成長率

53.6%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-49.6%
株主資本利益率	-51,181.9%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

Feb 18

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

Jan 11

収支内訳

GeoVax Labs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:GOVX 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 24	0	-28	6
31 Dec 23	0	-26	6
30 Sep 23	0	-24	6
30 Jun 23	0	-19	6
31 Mar 23	0	-16	5
31 Dec 22	0	-14	5
30 Sep 22	0	-22	4
30 Jun 22	0	-20	4
31 Mar 22	0	-19	4
31 Dec 21	0	-19	4
30 Sep 21	0	-6	3
30 Jun 21	1	-5	3
31 Mar 21	1	-4	3
31 Dec 20	2	-3	2
30 Sep 20	2	-2	2
30 Jun 20	2	-2	2
31 Mar 20	2	-2	2
31 Dec 19	1	-2	2
30 Sep 19	1	-2	2
30 Jun 19	1	-3	2
31 Mar 19	1	-3	2
31 Dec 18	1	-3	2
30 Sep 18	1	-2	1
30 Jun 18	1	-2	1
31 Mar 18	1	-2	1
31 Dec 17	1	-2	1
30 Sep 17	1	-3	2
30 Jun 17	1	-2	2
31 Mar 17	1	-3	2
31 Dec 16	1	-3	2
30 Sep 16	1	-3	2
30 Jun 16	0	-3	2
31 Mar 16	0	-3	2
31 Dec 15	0	-3	1
30 Sep 15	0	-3	2
30 Jun 15	1	-3	2
31 Mar 15	1	-3	2
31 Dec 14	1	-3	2
30 Sep 14	1	-3	2
30 Jun 14	2	-2	1
31 Mar 14	2	-2	2
31 Dec 13	2	-2	2
30 Sep 13	3	-2	2

質の高い収益: GOVXは現在利益が出ていません。

利益率の向上: GOVXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: GOVXは利益が出ておらず、過去 5 年間で損失は年間48.2%の割合で増加しています。

成長の加速: GOVXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: GOVXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: GOVXは現在利益が出ていないため、自己資本利益率 ( -51181.9% ) はマイナスです。

GeoVax Labs 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

Recent updates

GeoVax Labs Receives Letter from Nasdaq Due to Failure to Comply with Nasdaq’s Shareholder Approval Requirements Set Forth in Nasdaq Listing Rule 5635(d)

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

New minor risk - Shareholder dilution

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Price target decreased to US$5.50

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.66 loss in 2Q 2020)

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

First quarter 2021 earnings released: US$0.29 loss per share (vs US$2.54 loss in 1Q 2020)

Full year 2020 earnings released: US$2.14 loss per share

GeoVax Labs, Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

GeoVax Expands and Strengthens Intellectual Property Portfolio

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

New 90-day high: US$7.71

New 90-day high: US$5.95

過去基準チェック /06